15 November 2016
SCI's London Group in partnership with UCL's Chemical & Physical Society
UCL, London, UK
This event is no longer available for registration.
Department of Chemistry
University College London
20 Gordon Street
London, WC1H 0AJ
Tel: +44 (0) 20 7598 1594
This is a FREE event. No need to book. Please check this page for any updates or changes before attending the event.
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Read our event booking terms and conditions
Dr David Witty
Convergence Pharmaceuticals Ltd
David is a founding member of Convergence Pharmaceuticals Ltd, a company focused on the design and development of novel pain medications, where he is Chemistry Director and Operations Manager. Convergence spun out of GSK in 2010 and was acquired by Biogen in 2015, following successful Phase II studies.
David has worked as a medicinal chemist in multiple teams and programme leadership roles over more than 25 years and has particular interest in novel approaches to Drug Discovery and Medicinal therapeutic areas and led enzyme, receptor and ion channel programmes. He is also experienced in infrastructure and IT aspects of pharmaceutical research.
As a member of SCI for some 20 years he has worked on education and the promotion of best practice in medicinal chemistry through the delivery of Med.Chem. training courses, scientific symposia, publications and on-the-job training. From 2013-15 David served as Chairman of SCI's Fine Chemicals Group, and he is now a member of SCI's Board of Trustees. For the past decade David has also been the editor of 'Progress in Medicinal Chemistry' (Elsevier).
In his spare time, he likes fell walking with his wife and family.